BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36370473)

  • 1. An optimization study for targeted alpha therapy: Ion behaviours and dose calculations within ICRU-compact bone tissue.
    Kara A
    Appl Radiat Isot; 2023 Jan; 191():110552. PubMed ID: 36370473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting (223)Ra-dichloride.
    Pacilio M; Ventroni G; De Vincentis G; Cassano B; Pellegrini R; Di Castro E; Frantellizzi V; Follacchio GA; Garkavaya T; Lorenzon L; Ialongo P; Pani R; Mango L
    Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):21-33. PubMed ID: 26266887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison between Targeted Radionuclide Therapy of Bone Metastases Based on β-Emitting and α-Emitting Radionuclides.
    Sadremomtaz A; Masoumi M
    J Med Imaging Radiat Sci; 2019 Jun; 50(2):272-279. PubMed ID: 31176435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative imaging of 223Ra-chloride (Alpharadin) for targeted alpha-emitting radionuclide therapy of bone metastases.
    Hindorf C; Chittenden S; Aksnes AK; Parker C; Flux GD
    Nucl Med Commun; 2012 Jul; 33(7):726-32. PubMed ID: 22513884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selection of radionuclide(s) for targeted alpha therapy based on their nuclear decay properties.
    Ree SM; Greenwood H; Young JD; Roberts R; Livens FR; Heath SL; Sosabowski JK
    Nucl Med Commun; 2024 Jun; 45(6):465-473. PubMed ID: 38465420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor Activity of Novel Bone-seeking, α-emitting
    Juzeniene A; Bernoulli J; Suominen M; Halleen J; Larsen RH
    Anticancer Res; 2018 Apr; 38(4):1947-1955. PubMed ID: 29599310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Theoretical estimation of absorbed dose to organs in radioimmunotherapy using radionuclides with multiple unstable daughters.
    Hamacher KA; Sgouros G
    Med Phys; 2001 Sep; 28(9):1857-74. PubMed ID: 11585217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted alpha therapy: part I.
    Elgqvist J
    Curr Radiopharm; 2011 Jul; 4(3):176. PubMed ID: 22201706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computational modeling of radiobiological effects in bone metastases for different radionuclides.
    Liberal FDCG; Tavares AAS; Tavares JMRS
    Int J Radiat Biol; 2017 Jun; 93(6):627-636. PubMed ID: 28276897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Alpha emitter radium-223 dichloride: new therapy in castration-resistant prostate cancer with symptomatic bone metastases].
    Heinzer H; König F; Klutmann S
    Urologe A; 2014 Apr; 53(4):519-23. PubMed ID: 24604017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model.
    Henriksen G; Breistøl K; Bruland ØS; Fodstad Ø; Larsen RH
    Cancer Res; 2002 Jun; 62(11):3120-5. PubMed ID: 12036923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted alpha therapy using Radium-223: From physics to biological effects.
    Marques IA; Neves AR; Abrantes AM; Pires AS; Tavares-da-Silva E; Figueiredo A; Botelho MF
    Cancer Treat Rev; 2018 Jul; 68():47-54. PubMed ID: 29859504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted α Therapies for the Treatment of Bone Metastases.
    Zustovich F; Barsanti R
    Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29283383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer.
    Parker CC; Pascoe S; Chodacki A; O'Sullivan JM; Germá JR; O'Bryan-Tear CG; Haider T; Hoskin P
    Eur Urol; 2013 Feb; 63(2):189-97. PubMed ID: 23000088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted Alpha Therapy, an Emerging Class of Cancer Agents: A Review.
    ; Parker C; Lewington V; Shore N; Kratochwil C; Levy M; Lindén O; Noordzij W; Park J; Saad F
    JAMA Oncol; 2018 Dec; 4(12):1765-1772. PubMed ID: 30326033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling Cell and Tumor-Metastasis Dosimetry with the Particle and Heavy Ion Transport Code System (PHITS) Software for Targeted Alpha-Particle Radionuclide Therapy.
    Lee D; Li M; Bednarz B; Schultz MK
    Radiat Res; 2018 Sep; 190(3):236-247. PubMed ID: 29944461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative analysis of 11 different radioisotopes for palliative treatment of bone metastases by computational methods.
    Guerra Liberal FD; Tavares AA; Tavares JM
    Med Phys; 2014 Nov; 41(11):114101. PubMed ID: 25370676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Palliation of Extensive Metastatic Bone Disease With 223Ra-Dichloride α-Particle Therapy in a Patient With Malignant Hereditary Paraganglioma-Pheochromocytoma Syndrome With SDHB Mutation.
    Makis W; McCann K; McEwan AJ; Sawyer MB
    Clin Nucl Med; 2016 Feb; 41(2):144-7. PubMed ID: 26359562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An overview of targeted alpha therapy.
    Kim YS; Brechbiel MW
    Tumour Biol; 2012 Jun; 33(3):573-90. PubMed ID: 22143940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An alternative radiochemical separation strategy for isolation of Ac and Ra isotopes from high energy proton irradiated thorium targets for further application in Targeted Alpha Therapy (TAT).
    Baimukhanova A; Engudar G; Marinov G; Kurakina E; Dadakhanov J; Karaivanov D; Yang H; Ramogida CF; Schaffer P; Magomedbekov EP; Filosofov D; Radchenko V
    Nucl Med Biol; 2022; 112-113():35-43. PubMed ID: 35797877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.